Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Metrics to compare | PHPN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHPNPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.6x | −4.5x | −0.5x | |
PEG Ratio | −2.60 | 0.02 | 0.00 | |
Price/Book | −1.8x | 3.1x | 2.6x | |
Price / LTM Sales | - | 192.4x | 3.2x | |
Upside (Analyst Target) | - | 168.8% | 42.0% | |
Fair Value Upside | Unlock | 8.9% | 6.6% | Unlock |